CORDIS
Resultados de investigaciones de la UE

CORDIS

Español ES
A Systems medicine approach to chronic inflammatory disease

A Systems medicine approach to chronic inflammatory disease

Objetivo

"The SYSCID consortium aims to develop a systems medicine approach for disease prediction in CID. We will focus on three major CID indications with distinct characteristics, yet a large overlap of their molecular risk map: inflammatory bowel disease, systemic lupus erythematodes and rheumatoid arthritis. We have joined 15 partners from major cohorts and initiatives in Europe (e.g.IHEC, ICGC, TwinsUK and Meta-HIT) to investigate human data sets on three major levels of resolution: whole blood signatures, signatures from purified immune cell types (with a focus on CD14 and CD4/CD8) and selected single cell level analyses. Principle data layers will comprise SNP variome, methylome, transcriptome and gut microbiome. SYSCID employs a dedicated data management infrastructure, strong algorithmic development groups (including an SME for exploitation of innovative software tools for data deconvolution) and will validate results in independent retrospective and prospective clinical cohorts.
Using this setup we will focus on three fundamental aims : (i) the identification of shared and unique ""core disease signatures” which are associated with the disease state and independent of temporal variation, (ii) the generation of ""predictive models of disease outcome""- builds on previous work that pathways/biomarkers for disease outcome are distinct from initial disease risk and may be shared across diseases to guide therapy decisions on an individual patient basis, (iii) ""reprogramming disease""- will identify and target temporally stable epigenetic alterations in macrophages and lymphocytes in epigenome editing approaches as biological validation and potential novel therapeutic tool .
Thus, SYSCID will foster the development of solid biomarkers and models as stratification in future long-term systems medicine clinical trials but also investigate new causative therapies by editing the epigenome code in specific immune cells, e.g. to alleviate macrophage polarization defects."

Coordinador

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Dirección

Olshausenstrasse 40
24118 Kiel

Alemania

Tipo de actividad

Higher or Secondary Education Establishments

Aportación de la UE

€ 2 854 260

Participantes (14)

Ordenar alfabéticamente

Ordenar por aportación de la UE

Ampliar todo

KING'S COLLEGE LONDON

Reino Unido

Aportación de la UE

€ 919 083,75

VIB

Bélgica

Aportación de la UE

€ 1 181 518,75

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Reino Unido

Aportación de la UE

€ 1 061 022,50

UNIVERSITE DE LIEGE

Bélgica

Aportación de la UE

€ 1 016 900

UNIVERSITE DE GENEVE

Suiza

COMMA SOFT AG

Alemania

Aportación de la UE

€ 348 125

RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN

Alemania

Aportación de la UE

€ 1 259 351,25

UNIVERSITE DU LUXEMBOURG

Luxemburgo

Aportación de la UE

€ 1 115 040

SYDDANSK UNIVERSITET

Dinamarca

Aportación de la UE

€ 590 935

UNIVERSITAT DES SAARLANDES

Alemania

Aportación de la UE

€ 1 173 675

HUMANITAS UNIVERSITY

Italia

Aportación de la UE

€ 795 025

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Grecia

Aportación de la UE

€ 600 000

GENOS DOO ZA VJESTACENJE I ANALIZU

Croacia

Aportación de la UE

€ 880 050

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Alemania

Aportación de la UE

€ 661 250

Información del proyecto

Identificador del acuerdo de subvención: 733100

Estado

Proyecto en curso

  • Fecha de inicio

    1 Enero 2017

  • Fecha de finalización

    31 Marzo 2022

Financiado con arreglo a:

H2020-EU.3.1.1.

  • Presupuesto general:

    € 16 018 111,25

  • Aportación de la UE

    € 14 456 236,25

Coordinado por:

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Alemania